Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO(TM) in Canada from Knight

Executive Summary

• Profound Medical Corp. has regained exclusive Canadian distribution rights for its TULSA‑PRO® prostate therapy system from Knight Therapeutics.
• The transaction involved a one‑time cash payment of CDN $90,000 (US $64,000) and a 5% royalty on Canadian net sales for the next 15 years.
• Profound plans to expand the TULSA‑PRO business in Canada through its own sales team, additional clinical sites, and future reimbursement submissions following upcoming trial results.

Key Details

• Agreement Terms: One‑time cash consideration of CDN $90,000; ongoing royalty of 5% on Canadian net sales for a 15‑year term.
• Previous Arrangement: Knight Therapeutics had been the exclusive distributor since April 2015.
• Commercial Strategy: Profound will deploy its North American direct sales force and pursue additional Canadian sites (currently only Sunnybrook Health Sciences Centre) using an interim concierge service model.
• Regulatory Status: TULSA‑PRO is CE‑marked, Health Canada approved, and FDA 510(k) cleared.
• Clinical Context: More than 100 procedures have been performed at Sunnybrook; results from the Level I CAPTAIN trial (comparing TULSA to robotic radical prostatectomy) are expected in 2026 and will support provincial reimbursement applications.
• Future Opportunity: If provincial coverage is obtained, Profound anticipates broader adoption across Canadian hospitals.

Notable Quotes

“Knight has been a strong supporter of Profound… The launch of TULSA‑PRO in Canada … will be served best by Profound’s North American integrated commercial and clinical teams.” – Samira Sakhia, President & CEO, Knight Therapeutics

“Toronto’s renowned Sunnybrook Health Sciences Centre … has already performed more than 100 TULSA Procedures… we plan to use trial results to support applications for provincial coverage.” – Arun Menawat, CEO & Chairman, Profound Medical Corp.